Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs' antiplatelet effects

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 1, 2015, Pages 41-52

  Stepensky, David ^a   Rimon, Gilad ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

COX 1 and COX 2 enzymes; Dose and treatment schedule dependent effects; Drug drug interaction; NSAIDs; Pharmacokinetic pharmacodynamic modeling

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ETODOLAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC; TOLMETIN; VALDECOXIB; ANTITHROMBOCYTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BINDING; PTGS1 PROTEIN, HUMAN;

ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; COMPETITION; CRYSTALLOGRAPHY; DRUG BINDING; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME STRUCTURE; HEART INFARCTION; HUMAN; IC50; LOW DRUG DOSE; MORBIDITY; MORTALITY; REVIEW; THROMBOEMBOLISM; ANIMAL; BINDING COMPETITION; CHEMISTRY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BINDING, COMPETITIVE; CRYSTALLOGRAPHY; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY;

EID: 84918504660     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.971010     Document Type: Review

References (64)

1. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012;119:3016-23
2. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e89S-119S
3. Mescape drugs and diseases, aspirin monograph. Available from: http://reference.medscape.com/drug/zorprinbayer-buffered-aspirin-343279 [Accessed 21 September 2014]
4. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:199S-233S
5. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-301.
6. Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006;80:264-74.
7. Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six nonsteroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008;101:1060-3.
8. Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011;63:850-9.
9. Otto JC, Smith WL. Prostaglandin endoperoxide synthases-1 and-2. J Lipid Mediat Cell Signal 1995;12:139-56
10. Kang YJ, Mbonye UR, DeLong CJ, et al. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007;46:108-25
11. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82
12. Miyamoto T, Ogino N, Yamamoto S, et al. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976;251:2629-36
13. Feng L, Sun W, Xia Y, et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993;307:361-8
14. Smith WL, DeWitt DL, Shimokawa T, et al. Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents. Stroke 1990;21:IV24-8
15. Yokoyama C, Takai T, Tanabe T. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence. FEBS Lett 1988;231:347-51
16. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 1992;267:21438-45
17. Picot D, Garavito RM. Prostaglandin H synthase: implications for membrane structure. FEBS Lett 1994;346:21-5
18. Yuan C, Rieke CJ, Rimon G, et al. Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci USA 2006;103:6142-7
19. Yuan C, Sidhu RS, Kuklev DV, et al. Cyclooxygenase allosterism, fatty acidmediated cross-talk between monomers of cyclooxygenase homodimers. J Biol Chem 2009;284:10046-55
20. Futaki N, Arai I, Hamasaka Y, et al. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 1993;45:753-5
21. Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994;47:55-9
22. Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ 2005;330:440
23. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9
24. SoRelle R. Rofecoxib use increases acute myocardial infarction risk. Circulation 2004;109:e9039-40
25. Burde T, Rimon G. On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. Eur J Pharmacol 2002;453:167-73
26. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001;98:14583-8
27. Rosenstock M, Danon A, Rimon G. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim Biophys Acta 1999;1440:127-37
28. Rimon G, Sidhu RS, Lauver DA, et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci USA 2010;107:28-33.
29. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
30. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002;42:1027-30.
31. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15
32. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-13
33. Benedek IH, Joshi AS, Pieniaszek HJ, et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995;35:1181-6
34. Bochner F, Williams DB, Morris PM, et al. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988;35:287-94
35. Armstrong PC, Truss NJ, Ali FY, et al. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. J Thromb Haemost 2008;6:1933-43
36. Fitzgerald DJ, Fitzgerald GA. Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res 2013;112:174-94
37. Polzin A, Zeus T, Schror K, et al. Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease. J Am Coll Cardiol 2013;62:1725-6
38. Hong Y, Gengo FM, Rainka MM, et al. Population pharmacodynamic modelling of aspirin-and ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet 2008;47:129-37
39. Awa K, Satoh H, Hori S, et al. Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J Clin Pharm Ther 2011;37:469-74.
40. FDA. Information for Healthcare Professionals: concomitant use of ibuprofen and aspirin. 2006. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm125222.htm [Accessed 8 August 2013]
41. Wollenberg L, Iyer V, Robson M, et al. Application of a mechanism-based population pharmacodynamic model on the time-course of ex-vivo platelet aggregation when naproxen and aspirin are administered alone and in combination. Poster presentation at the American College of Clinical Pharmacy Annual Meeting; 21-24 October 2012;
42. Goltsov A, Maryashkin A, Swat M, et al. Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations. Eur J Pharm Sci 2009;36:122-36
43. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011;9:1705-12
44. Lane DA, Lip GY. Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurol 2010;9:1140-2
45. Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned Curr Cardiol Rep 2014;16:480
46. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2014. [Epub ahead of print]
47. Wisloff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics 2014;32:601-12
48. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605
49. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-9
50. Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke 2012;43:3291-7
51. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50
52. Holmes MD, Chen WY, Li L, et al. Aspirin intake and survival after breast cancer. J Clin Oncol 2010;28:1467-72
53. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601
54. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-6
55. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 2009;53:667-77
56. Renda G, Zurro M, Malatesta G, et al. Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. Haematologica 2010;95:2095-101
57. Raffa RB, Gudin JA, Nalamachu S, et al. 'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure. J Clin Pharm Ther 2014;39:455-6
58. Tolmetin prescribing information. Available from: http://www.drugs.com/monograph/tolectin.html [Accessed 3 July 2014]
59. Piroxicam prescribing information. Available from: http://www.drugs.com/pro/piroxicam.html [Accessed 3 July 2014]
60. Mefenamic acid prescribing information. Available from: http://www.drugs.com/pro/mefenamic-acid.html [Accessed 3 July 2014]
61. Valdecoxib prescribing information. Available from: http://www.drugs.com/pro/bextra.html [Accessed 3 July 2014]
62. Etoricoxib prescribing information. Available from: http://www.drugs.com/international/etoricoxib.html [Accessed 3 July 2014]
63. Sorbera LA, Castaner RM, Silvestre J, et al. Etoricoxib: analgesic drug, antiarthritic, cyclooxygenase-2 inhibitor. Drugs Future 2001;26:346
64. Kulkarni SK, Jain NK, Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol 2000;22:291-8